Psoriasis: Next-Line Treatment When Oral Systemic Monotherapy Has Not Achieved PASI 75

This protocol addresses psoriasis management in patients whose oral systemic nonbiologic monotherapy did not produce sufficient skin clearance after an adequate treatment course.

Previous Treatment — Failure Condition

Prior therapy: oral systemic nonbiologic monotherapy — including agents such as methotrexate, apremilast, acitretin, tofacitinib, or fumaric acid esters used as a single agent.

Escalation trigger: failure to achieve PASI 75 (a 75% improvement in the Psoriasis Area and Severity Index) or clear / almost clear skin after 16 weeks of treatment.

Next-Line Approach — Partial Overview

The protocol escalates to a combination strategy that pairs a systemic agent with a phototherapy modality, targeting more rapid skin clearing at lower cumulative exposure to each individual treatment than monotherapy alone.

Full regimen details, sequencing, and monitoring criteria are in the complete protocol →

Clinical Goal

More rapid skin clearing, with clear or almost clear skin as the target outcome.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.jaad.2020.02.044

Combination therapy with methotrexate and NB-UVB phototherapy can be considered for adult patients with generalized plaque psoriasis to enhance efficacy and lower cumulative doses of both treatments.

Methotrexate has also been used with NB-UVB phototherapy. This combination results in increased efficacy and more rapid skin clearing at lower cumulative doses of methotrexate and UVB compared with monotherapy with either treatment.

View source ↗